에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Social Media

Exclusives

Tech

Trading Ideas

LAES

MRVL

SNAP

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스냅, 실스크, 버티브, 다나허 및 마벨 테크놀로지

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

General

화요일에, 다나허(NYSE:DHR)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, 컨센서스 55억 9천만 달러를 상회했다고 보고했다. 가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.

다나허의 3분기 실적은 바이오프로세싱 주문 증가로 인해 증가, 분석가는 주식 등급 유지

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 23%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $34,500, and 12, calls, for a total amount of $814,222.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $230.0 for Danaher during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $140.0 to $230.0 in the last 30 days. 
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740170729_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.1</td>
<td>$14.1</td>
<td>$14.1</td>
<td>$210.00</td>
<td>$338.7K</td>
<td>468</td>
<td align="right">2</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$210.00</td>
<td>$103.8K</td>
<td>1.5K</td>
<td align="right">196</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.8</td>
<td>$212.50</td>
<td>$66.1K</td>
<td>719</td>
<td align="right">620</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.4</td>
<td>$9.3</td>
<td>$10.0</td>
<td>$210.00</td>
<td>$45.0K</td>
<td>933</td>
<td align="right">0</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$85.5</td>
<td>$84.4</td>
<td>$85.5</td>
<td>$140.00</td>
<td>$42.7K</td>
<td>6</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
In light of the recent options history for Danaher, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Danaher</h3>
<ul>
<li>With a trading volume of 3,978,641, the price of DHR is up by 1.46%, reaching $210.98.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 60 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $252.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Danaher with a target price of $240. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $265. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Danaher with a target price of $260. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $258. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Danaher, targeting a price of $240. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Danaher's Options Frenzy: What You Need to Know

Dividends

Danaher Increases Quarterly Dividend From $0.27 To $0.32

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>)&nbsp;released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">but beating the consensus of 41 cents</a>.
The bioprocessing technology reported sales of $167.55 million, slightly up from $166.6 million a year ago, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43844804/repligen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $167.67 million</a>.
Olivier Loeillot, President and Chief Executive Officer of Repligen, said, "During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13%, excluding COVID-19, overcoming two points of currency headwind. Total orders outpaced sales by 6%, driven by our Filtration and Analytics franchises&#8230;While we continue to monitor China and emerging biotech,&nbsp;the overall bioprocessing market is returning to growth. Our order momentum during the second half gives us confidence that we can achieve our 2025 guidance."
Guidance:&nbsp;Repligen expects 2025 sales of $685 million—$710 million, with organic growth of 9.5%—13.5% and non-COVID revenue growth of 10%—14% compared to the consensus of $694.86 million.
The company expects adjusted EPS of $1.67—$1.76 compared to the consensus of $1.73.
William Blair says Repligen's Q4 results and 2025 outlook confirm that the bioprocessing industry is recovering strongly, with growth expected to return to normal levels next year.
Repligen's guidance reflects strong quarterly momentum, signaling a market recovery.
Compared to peers like Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) and Avantor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NASDAQ">AVTR</a>), which project mid-to-high single-digit growth in bioprocessing, Repligen's outlook highlights its strong product portfolio and customer positioning that have driven consistent above-market growth.
Since Repligen focuses solely on bioprocessing and has minimal exposure to risks in NIH-funded research, academia, or China, analyst Matt Larew believes its guidance is more predictable than competitors with broader market and geographic exposure.
Price Action: RGEN stock is up 8.16% at $163.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43853635/hf-sinclair-reports-mixed-q4-results-with-weak-earning-weak-refining-margins-drive-93-drop-in-adjusted-ebitda" target="_blank" rel="noreferrer noopener">HF Sinclair Reports Mixed Q4 Results, Weak Refining Margins Drive 93% Drop In Adjusted EBITDA</a></li>
</ul>
Image via Repligen

RGEN

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

In the current session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is trading at $204.95, after a 0.01% decrease. Over the past month, the stock decreased by 16.56%, and in the past year, by 19.25%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1740056425_0.png" alt="Past Year Chart" />

<h3>A Look at Danaher P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 95.78 in the Life Sciences Tools &amp; Services industry, Danaher Inc. has a lower P/E ratio of 38.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740056425_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Danaher

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$77.50</td>
<td>$27.5K</td>
<td>206</td>
<td>6.0K</td>
</tr>
<tr>
<td>EYPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$49.7K</td>
<td>431</td>
<td>1.0K</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$100.00</td>
<td>$37.1K</td>
<td>475</td>
<td>384</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$108.00</td>
<td>$38.3K</td>
<td>45</td>
<td>339</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$162.5K</td>
<td>3.5K</td>
<td>222</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$110.4K</td>
<td>5.0K</td>
<td>183</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$240.00</td>
<td>$28.4K</td>
<td>5</td>
<td>136</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$257.3K</td>
<td>1.3K</td>
<td>134</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$200.00</td>
<td>$106.5K</td>
<td>203</td>
<td>95</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$550.00</td>
<td>$171.4K</td>
<td>710</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 62 contract(s) at a $77.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.5K, with a price of $445.0 per contract. There were 206 open contracts at this strike prior to today, and today 6063 contract(s) were bought and sold. 
• For EYPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), we notice a put option sweep that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $5.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $95.0 per contract. There were 431 open contracts at this strike prior to today, and today 1002 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option sweep that happens to be bearish, expiring in 304 day(s) on December 19, 2025. This event was a transfer of 24 contract(s) at a $100.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $1553.0 per contract. There were 475 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on March 7, 2025. This event was a transfer of 276 contract(s) at a $108.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $139.0 per contract. There were 45 open contracts at this strike prior to today, and today 339 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $162.5K, with a price of $3250.0 per contract. There were 3527 open contracts at this strike prior to today, and today 222 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 96 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $110.4K, with a price of $1150.0 per contract. There were 5079 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• Regarding WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 16 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $1780.0 per contract. There were 5 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option sweep with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 83 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $257.3K, with a price of $3100.0 per contract. There were 1316 open contracts at this strike prior to today, and today 134 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 82 contract(s) at a $200.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1300.0 per contract. There were 203 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 40 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $171.4K, with a price of $4285.0 per contract. There were 710 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

GILD

TMDX

10 Health Care Stocks Whale Activity In Today's Session

Deep-pocketed investors have adopted a bearish approach towards Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DHR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Danaher. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 56% bearish. Among these notable options, 20 are puts, totaling $644,075, and 3 are calls, amounting to $143,154.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $202.5 to $230.0 for Danaher over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Danaher's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale trades within a strike price range from $202.5 to $230.0 in the last 30 days. 
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739380528_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.3</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$202.50</td>
<td>$63.4K</td>
<td>79</td>
<td align="right">410</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$8.2</td>
<td>$7.8</td>
<td>$8.0</td>
<td>$210.00</td>
<td>$44.8K</td>
<td>246</td>
<td align="right">61</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$31.0</td>
<td>$30.6</td>
<td>$30.87</td>
<td>$230.00</td>
<td>$40.0K</td>
<td>1.6K</td>
<td align="right">103</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$31.0</td>
<td>$30.6</td>
<td>$30.87</td>
<td>$230.00</td>
<td>$40.0K</td>
<td>1.6K</td>
<td align="right">107</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$30.8</td>
<td>$30.4</td>
<td>$30.6</td>
<td>$230.00</td>
<td>$36.7K</td>
<td>1.6K</td>
<td align="right">674</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Following our analysis of the options activities associated with Danaher, we pivot to a closer look at the company's own performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,166,471, with DHR's price down by -0.72%, positioned at $200.16.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What The Experts Say On Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $258.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Danaher, maintaining a target price of $240. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $277. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $260. 
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $275. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $240. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $110,000, and 7, calls, for a total amount of $1,494,500.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $230.0 for Danaher, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $120.0 to $230.0 in the last 30 days. 
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738957522_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.4</td>
<td>$13.1</td>
<td>$13.3</td>
<td>$220.00</td>
<td>$997.5K</td>
<td align="right">69</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.3</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$220.00</td>
<td>$336.5K</td>
<td align="right">69</td>
<td>5</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$22.6</td>
<td>$21.2</td>
<td>$22.0</td>
<td>$230.00</td>
<td>$110.0K</td>
<td align="right">389</td>
<td>52</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.64</td>
<td>$210.00</td>
<td>$45.0K</td>
<td align="right">683</td>
<td>132</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.9</td>
<td>$12.8</td>
<td>$12.9</td>
<td>$210.00</td>
<td>$32.2K</td>
<td align="right">92</td>
<td>47</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Following our analysis of the options activities associated with Danaher, we pivot to a closer look at the company's own performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,853,407, the DHR's price is down by -0.06%, now at $209.89. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 74 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Danaher Unusual Options Activity For February 07

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and recommended buying the same. &#8220;I think you've got a <a href="https://www.benzinga.com/quote/NEE/earnings">good one,&#8221; he added</a>.
On Jan. 24, NextEra Energy Inc posted in-line earnings for the fourth quarter and said it continues to expect adjusted EPS of $3.45-$3.70 for FY25.
<h3 class="wp-block-heading">Cramer&#8217;s Take On Tech Stocks</h3>
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) has missed the quarter too often, Cramer said. &#8220;If you want to be in that, you want to be in Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>).&#8221; The San Francisco-based company will release financial results for the fourth quarter after the closing bell on Wednesday, Feb. 12.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) is &#8220;up in a straight line, it's a parabolic move.&#8221; He noted that although it's a good company, but he can't recommend parabolic stocks. &#8220;Let that one come in,&#8221; he added. The San Jose, California-based company, on Feb. 4, posted better-than-expected earnings for its fourth quarter.</li>
</ul>
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been bad for him, the Mad Money host said. &#8220;That last quarter was terrible, and, frankly, they were very smug on the call talking about how good it was, and that was a very ill-advised strategy that they adopted, and I don't like it.&#8221;
Supporting his view, Raymond James analyst Andrew Cooper, on Feb. 3, downgraded Danaher from Outperform to Market Perform.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is Jeffrey Gendell's [Chief Executive Officer for IES Holdings] company, Cramer said. &#8220;He is a, just an amazing man.&#8221;
As per the recent earnings report, IES, on Tuesday, reported quarterly earnings of $2.64 per share, up from $1.86 per share from the same period last year. The company reported $749.50 million in sales during the quarter, compared to $634.40 million the same period last year.
Cramer said Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is a &#8220;really great&#8221; company, but he doesn't want to recommend the stock. &#8220;It's the best house in a bad neighborhood, and we don't want to be in bad neighborhoods,&#8221; he added.
In the recent news, Schlumberger's OneSubsea joint venture on Tuesday entered an agreement with Vår Energi to deliver a subsea production systems work scope, aimed at supporting multiple upcoming oil and gas developments on the Norwegian Continental Shelf.
Price Action:
<ul>
<li>NextEra Energy shares gained 0.1% to settle at $69.27 on Thursday.</li>
<li>Fastly shares dipped 2.4% to close at $9.99 during the session.</li>
<li>Danaher shares fell 1% to settle at $210.01.</li>
<li>IES shares climbed 8.4% to close at $242.10 on Thursday.</li>
<li>SLB shares fell 1.9% to settle at $40.05.</li>
<li>A10 Networks shares fell 1.3% to close at $20.55 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43536198/top-2-industrials-stocks-that-are-ticking-portfolio-bombs">Top 2 Industrials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ATEN

FSLY

IESC

Jim Cramer Likes This Utilities Stock: 'I Think You've Got A Good One'

High-rolling investors have positioned themselves bullish on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Danaher. This is not a typical pattern.
The sentiment among these major traders is split, with 61% bullish and 38% bearish. Among all the options we identified, there was one put, amounting to $26,400, and 12 calls, totaling $9,798,273.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $240.0 for Danaher, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Danaher stands at 1815.33, with a total volume reaching 6,881.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $220.0 to $240.0, throughout the last 30 days.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738607423_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$28.6</td>
<td>$27.3</td>
<td>$28.6</td>
<td>$240.00</td>
<td>$7.8M</td>
<td>2.5K</td>
<td>3.4K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$30.1</td>
<td>$26.5</td>
<td>$29.9</td>
<td>$240.00</td>
<td>$299.0K</td>
<td>2.5K</td>
<td>0</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.6</td>
<td>$27.4</td>
<td>$29.6</td>
<td>$240.00</td>
<td>$296.0K</td>
<td>2.5K</td>
<td>300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.3</td>
<td>$29.4</td>
<td>$240.00</td>
<td>$294.0K</td>
<td>2.5K</td>
<td>630</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.2</td>
<td>$29.4</td>
<td>$240.00</td>
<td>$294.0K</td>
<td>2.5K</td>
<td>510</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Danaher</h3>
<ul>
<li>Currently trading with a volume of 2,405,344, the DHR's price is down by -2.51%, now at $217.16. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>Professional Analyst Ratings for Danaher</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $256.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $260. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $258. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Danaher with a target price of $240. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Danaher, which currently sits at a price target of $240. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Danaher, maintaining a target price of $285. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Danaher's Options: A Look at What the Big Money is Thinking

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Andrew Cooper downgraded the rating for Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Outperform to Market Perform. Danaher shares closed at $222.74 on Friday. <a href="https://www.benzinga.com/quote/DHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Rick Paterson downgraded FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Buy to Hold and lowered the price target from $365 to $283. FedEx shares closed at $264.87 on Friday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Shrenik Kothari downgraded CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Outperform to Neutral but raised the price target from $390 to $430. CrowdStrike shares closed at $398.07 on Friday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Michael Lavery downgraded the rating for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Overweight to Neutral and lowered the price target from $245 to $200. Constellation Brands shares closed at $180.80 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Carlos De Alba downgraded United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Equal-Weight and maintained the price target of $39. United States Steel shares closed at $36.85 on Friday. <a href="https://www.benzinga.com/quote/X/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FDX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-1024x527.png" alt="" class="wp-image-762952" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

CRWD

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Raymond James analyst Andrew Cooper downgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Outperform to Market Perform.

Raymond James Downgrades Danaher to Market Perform

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.19% on an annualized basis producing an average annual return of 14.69%. Currently, Danaher has a market capitalization of $160.47 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $390.71 today based on a price of $223.16 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738269014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

RBC Capital analyst Conor McNamara reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $299 to $277.

RBC Capital Reiterates Outperform on Danaher, Lowers Price Target to $277

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $268 to $258.

Baird Maintains Outperform on Danaher, Lowers Price Target to $258

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported weaker-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/dhr/earnings">earnings on Wednesday</a>.
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
Rainer M. Blair, President and Chief Executive Officer, stated, "Good execution by our team also drove solid cash flow and operating margin expansion."
Danaher said it expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Danaher shares fell 9.7% to close at $223.73 on Wednesday.
These analysts made changes to their price targets on Danaher following earnings announcement.
<ul>
<li>Barclays analyst Luke Sergott maintained Danaher with an Equal-Weight and lowered the price target from $275 to $240.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Danaher with an Equal-Weight and cut the price target from $280 to $240.</li>
</ul>
Considering buying DHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png" alt="" class="wp-image-758143" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261.png 1120w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $280 to $240.

Wells Fargo Maintains Equal-Weight on Danaher, Lowers Price Target to $240

Barclays analyst Luke Sergott maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $275 to $240.

Barclays Maintains Equal-Weight on Danaher, Lowers Price Target to $240

Analysts' ratings for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $275.0, a high estimate of $290.00, and a low estimate of $260.00. Experiencing a 6.78% decline, the current average is now lower than the previous average price target of $295.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738188044_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Danaher among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$265.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Danaher's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Danaher's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Danaher analyst ratings.</a>
<h2>Get to Know Danaher Better</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Danaher's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.09%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA stands out, surpassing industry averages. With an impressive ROA of 1.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Danaher Stock

Jefferies analyst Tycho Peterson maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $260.

Jefferies Maintains Buy on Danaher, Lowers Price Target to $260

Press Releases

Danaher to Present at J.P. Morgan Healthcare Conference

Danaher Announces Investment Partnership in Innovaccer Inc.

Danaher CEO to Comment on Financial Performance

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

Compass Minerals Announces Senior Leadership Team Appointments

Danaher Reports Fourth Quarter and Full Year 2024 Results

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Danaher Increases Quarterly Dividend

Danaher Announces Appointment of Charles Lamanna to Danaher Board

MRVI

MSFT

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Citigroup

RBC Capital

Baird

Wells Fargo

Barclays

매주, 벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 12월 13일로 끝나는 주간의 벤징가 ‘스톡 위스퍼' 지수의 개요:
1. 스냅 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>):
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div>
<div class="relative w-fit"></div>
</div>
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div class="flex items-center ml-2 text-sm text-blue-500">소셜 미디어 및 메신저 회사인 스냅은 벤징가 독자들로부터 강한 관심을 받았다. 이는 미국에서 틱톡 <a style="font-size: revert;" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" target="_blank" rel="noopener">금지 운동이 계속되고 있는 것</a>과 관련이 있을 가능성이 크다.</div>
</div>
</div>
</div>
스냅과 틱톡의 소셜 미디어 경쟁자인 페이스북, 인스타그램 및 레딧 등은 틱톡이 금지될 경우 이점을 누릴 수 있다. 최근 틱톡은 미국 항소 법원과의 싸움에서 패배했으며, 모회사 바이트댄스는 2025년 1월 19일까지 미국 자회사를 비중국인 소유자에게 매각하지 않으면 앱 스토어에서 플랫폼이 제거된다는 기한을 받았다.
이것이 스냅에게는 긍정적인 소식이 될 수 있지만, 금지 조치는 아직 끝나지 않았으며, 바이트댄스가 계속해서 싸울 것이란 우려와 함께 도널드 트럼프 대통령 당선자가 백악관을 인수할 때 금지 조치를 중단할 수 있다는 우려도 있다. 또한 스냅과 다른 소셜 미디어 플랫폼들은 <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube" target="_blank" rel="noopener">여러 국가</a>와 주들에서 사용 연령 제한으로 인해 중단 조치를 받을 수 있다. 주가가 더 하락할 수 있다.
스냅의 주가는 금요일 0.62% 하락한 11.31달러에 마감되었다. 이번 주에는 9.52% 하락했으며, 2024년 연초 대비 주가가 29.93% 하락했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
2. 실스크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>):
마이크로칩 회사인 실스크(SEALSQ)는 드론과 관련된 여러 뉴스로 인해 주가가 급등했다. 이 회사는 패럿(Parrot)과 에이지이글(AgEagle)과의 <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42447155/sealsq-corp-shares-are-up-by-more-than-90-what-you-need-to-know" target="_blank" rel="noopener">파트너십을 발표</a>했다.
이 회사는 2025년에 새로운 양자 저항 보안 칩 포트폴리오를 출시할 계획이다. 이로 인해 주가가 Benzinga 독자들의 주목을 받을 수 있게 된다. 이러한 칩에 대한 테스트가 진행 중이며, 실스크는 IC 알프스(IC&#8217;ALPS)와의 <a href="https://www.benzinga.com/24/12/42466578/whats-going-on-with-sealsq-corp-today" target="_blank" rel="noopener">파트너십을 발표</a>하여 보안 애플리케이션 전용 집적 회로의 개발을 가속화했다.
&#8220;우리는 민첩성과 혁신을 결합함으로써 글로벌 반도체 산업에서 우수성의 기준을 설정하고 있다&#8221;고 실스크의 CTO인 장 피에르 앙구앙(Jean Pierre Enguent)가 말했다.
드론 시장은 상업용 및 군용 드론 애플리케이션의 증가로 인해 투자자들이 주목하고 있는 핫한 시장이다. 실스크의 주가는 이번 주에 297.82% 급등했다. 금요일 이 주식은 5.41% 하락한 1.75달러에 마감했으나 이후 시간외 거래에서 10.29% 급등했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
3. 버티브 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>):
필수 전력 및 인프라 회사인 버티브(Vertiv)는 이번 주에 독자들로부터 강한 관심을 받았다.
뱅크 오브 아메리카의 애널리스트인 앤드류 오빈(Andrew Obin)은 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42072226/vertivs-earnings-estimates-raised-by-analyst-amid-improved-margin-outlook" target="_blank" rel="noopener">최근 주식에 대해 매수 등급을 재확인</a>하고 목표 주가를 150달러로 설정했다. 이 애널리스트는 이 회사가 2024년부터 2029년까지의 유기적 매출 성장 전망을 12%-14%로 상향 조정했다고 밝혔다. 다른 애널리스트들도 최근 버티브에 대한 의견을 추가했으며, 바클레이즈는 주식을 중립 등급으로 시작하고 목표 주가를 142달러로 <a href="https://www.benzinga.com/quote/VRT/analyst-ratings" target="_blank" rel="noopener">설정</a>했으며, 씨티그룹은 매수 등급을 유지하고 목표 주가를 141달러에서 155달러로 상향 조정했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
4. 다나허 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>):
과학 기기 제조 회사인 다나허(Danaher)는 이번 주에 독자들로부터 증가된 관심을 받았다.
이 주식은 이전에 <a href="https://www.benzinga.com/top-stories/24/06/39551432/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noopener">6월에</a> 주식 속삭임 지수에 등장했으며, 애널리스트의 업그레이드가 주가를 상승시켰다. 뱅크 오브 아메리카는 중립에서 매수로 주식을 상향 조정하고, 목표 주가를 290달러로 설정했다. 이 애널리스트는 전략적 파트너십과 가격 책정이 향후 성장에 기여할 수 있다고 말했다.
다나허는 3분기 재무 결과를 10월에 발표했으며, 주당 순이익과 매출 모두 시장 예상을 초과했다. 이 회사는 매출과 주당 순이익 모두에서 10분기 연속으로 애널리스트 예상을 초과했다. 4분기 실적은 1월에 발표될 예정이며, 이는 주식에 대한 미래 촉매제가 될 수 있다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
5. 마벨 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>):
반도체 주식인 마벨은 동료들이 실적을 발표하고 회사가 12월 3일에 3분기 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A7%88%EB%B2%A8-%ED%85%8C%ED%81%AC%EB%86%80%EB%A1%9C%EC%A7%80-3%EB%B6%84%EA%B8%B0-%ED%98%B8%EC%8B%A4%EC%A0%81-%EB%B0%8F-4%EB%B6%84%EA%B8%B0-%EA%B0%95%EB%A0%A5%ED%95%9C-%EC%A0%84%EB%A7%9D-%EB%B0%9C/" target="_blank" rel="noopener">재무 결과를 발표</a>한 지 2주도 채 안 된 시점에서 주가가 상승하고 있다. 이 회사는 매출과 주당 순이익 모두에서 애널리스트의 예상치를 초과했다.
마벨의 CEO 맷 머피(Matt Murphy)는 회사의 4분기 전망이 맞춤형 AI 실리콘 프로그램의 대량 생산에 의해 주도되고 있음을 강조했다. 이 회사는 최근 데이터 센터를 위한 새로운 인터커넥트 포트폴리오 칩의 <a href="https://www.benzinga.com/news/contracts/24/12/42432652/marvell-debuts-game-changing-lpo-chipset-for-data-centers-details" target="_blank" rel="noopener">가용성을 발표</a>했다. 이는 AI 기반 데이터 센터가 인터커넥트 솔루션 최적화의 필요성을 높일 수 있기 때문이다.
여러 애널리스트들은 이 회사의 3분기 재무 결과 발표 후 <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/12/42321281/marvell-technology-posts-solid-q3-beat-analysts-raise-forecasts-expect-40-50-earnings-growth" target="_blank" rel="noopener">주가 목표를 상향 조정</a>했다. 금요일 이 주식은 10.79% 급등한 120.77달러에 마감되었다. 주가는 2024년 연초 대비 107.62% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">여기에서</a> Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.
여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%ED%94%84%EB%A1%9C%ED%83%80%EB%9D%BC-%EB%A7%88%EB%9D%BC-%ED%8A%B8%EB%A0%88/" target="_blank" rel="noopener">12월 7일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%82%AC%EC%9D%B4%EB%A8%BC-%ED%94%84%EB%A1%9C%ED%8D%BC%ED%8B%B0-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noreferrer noopener">11월 30일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5-%EB%82%98%EC%9D%B4%ED%82%A4-%EC%98%A4%ED%86%A0/" target="_blank" rel="noreferrer noopener">11월 23일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A1%EC%86%90-%EC%8A%A4%EB%85%B8%EC%9A%B0%ED%94%8C%EB%A0%88%EC%9D%B4-%EC%97%A0/" target="_blank" rel="noreferrer noopener">11월 16일</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 스냅, 실스크, 버티브, 다나허 및 마벨 테크놀로지

화요일에, 다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, <a href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" target="_blank" rel="noreferrer noopener">컨센서스 55억 9천만 달러</a>를 상회했다고 보고했다.
가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.
이 회사는 2024년 바이오프로세싱 핵심 매출이 낮은 한 자릿수로 감소할 것으로 예상하고 있으며, 세파이드(Cepheid) 2024 호흡기 매출은 이전 지침 16억 달러에 비해 약 17억 달러가 될 것으로 예상한다.
윌리엄 블레어(William Blair)는 도나허의 3분기 실적이 특히 바이오프로세싱의 지속적인 회복과 관련하여 기대에 부합했다고 보고했다. 그러나 자본 지출은 여전히 약세이다.
이 애널리스트는 회복 테마가 예상대로 진행되고 있으며, 결과가 분기 중 산업 컨퍼런스 업데이트에서 본 유사한 트렌드를 반영하고 있다고 강조했다.
3분기 B2B는 약 1.0배로 개선되어 1년 전의 0.80배에서 상승했으며 순차 주문의 높은 한 자릿수 증가가 바이오프로세싱 반등을 더욱 뒷받침했다.
장비 부문에서 생명과학 장비는 예측 및 분기 내 관찰과 일치하여 한 자릿수 중반 감소를 보였다.
한편, 진단 부문은 잘 수행되었으며, 세파이드의 호흡기 매출은 다시 한 번 기대를 초과했다.
가이던스에 대해 경영진은 생명공학 분야의 4분기에 중간에서 높은 한 자릿수 핵심 성장률을 기대한다. 이 애널리스트는 컨퍼런스 콜의 초점이 바이오프로세싱의 4분기 종료율, 2025년 초기 통찰력, 자본 장비의 약세 및 중국에 대한 업데이트된 생각이 될 것으로 예상하고 있다.
윌리엄 블레어는 아웃퍼폼 등급을 유지하고 있다. 골드만삭스는 중립 등급을 유지하며, <a href="https://www.benzinga.com/quote/dhr/analyst-ratings">목표 주가를 250달러로 설정</a>했다.
주가 움직임: 다나허의 주식은 화요일 3.97% 하락한 261.28달러에 마감되었다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Danaher

뉴스

에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

토요일, 12월 14, 2024

화요일, 10월 22, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌